Lipid-lowering treatment in metabolic syndrome;Léčba dyslipidemie u metabolického syndromu

Vnitrni Lekarstvi

Volumn 55, Issue 7-8, 2009, Pages 626-630

  Štulc, Tomáš ^a   Ceska R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular risk; Dyslipidemia; Fibrates; Lipid lowering drugs; Metabolic syndrome; Statins

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RIMONABANT; LIPID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; REVIEW; BLOOD; RISK REDUCTION;

DYSLIPIDEMIAS; HUMANS; LIPIDS; METABOLIC SYNDROME X; RISK REDUCTION BEHAVIOR;

EID: 70349266262     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Ford ES, Abbasi F, Reaven GM et al. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005; 181: 143-148. (Pubitemid 40804705)
3. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716. (Pubitemid 35403784)
4. Isomaa B, Almren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689. (Pubitemid 32893993)
5. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22 (Suppl 3): C10-C13.
6. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
7. Cífková R, Škodová Z. Dlouhodobé trendy hlavních rizikových faktorů kardiovaskulá rních onemocnění v české populaci. Čas Lék Čes 2004; 143: 219-226. (Pubitemid 38568819)
8. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197. (Pubitemid 46426694)
9. Eilat-Adar S, Eldar M, Goldbourt U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol 2005; 161: 352-358. (Pubitemid 40256207)
10. Cholesterol Treatment Triallists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
11. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
12. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
13. Birjmohun RS, Hutten BA, Kastelein JJ et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-197. (Pubitemid 40094724)
14. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
15. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101: 20B-26B.
16. Drazen JM, D'Agostino RB, Ware JH et al. Ezetimibe and cancer - an uncertain association. N Engl J Med 2008; 359: 1398-1399.
17. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122. (Pubitemid 350146106)